Impact of minimal residual diseases status and depth of response on survival outcomes in blinatumomab-treated acute lymphoblastic leukemia: A systematic review and meta-analysis

This review aimed to assess the effectiveness of blinatumomab in treating relapsed/refractory acute lymphoblastic leukemia (R/R ALL). The analysis of 21 studies showed that blinatumomab led to an improvement in overall survival (OS) and disease-free survival (DFS). The complete remission rate was 51.6% and the MRD response was 64.6%. Blinatumomab demonstrated a favorable safety profile compared to standard chemotherapy.